Can you provide an overview of transthyretin (TTR) amyloidosis, including its pathophysiology, clinical manifestations, diagnosis, and treatment options?

Transthyretin (TTR) Amyloidosis: A Comprehensive Overview

What is ATTR Amyloidosis?

ATTR amyloidosis is a progressive, life-threatening systemic disease caused by misfolded transthyretin protein that forms insoluble amyloid fibrils depositing in multiple organs, most critically the heart and peripheral nerves, with a median survival of 2-6 years after cardiac diagnosis if untreated 1.

TTR is a protein produced primarily by the liver that normally transports thyroid hormone and vitamin A. When it misfolds, it aggregates into amyloid fibrils that infiltrate tissues and organs 1, 2.

Two Distinct Forms

Wild-Type ATTR (ATTRwt)

• Occurs from aggregation of normal TTR protein
• Primarily affects men over 70 years old
• Manifests predominantly as cardiomyopathy
• More common than previously recognized 1, 3

Variant ATTR (ATTRv, formerly hereditary ATTR)

• Results from genetic mutations in the TTR gene
• Transmitted in autosomal-dominant pattern with variable penetrance
• Can manifest as cardiomyopathy, polyneuropathy, or mixed phenotypes
• Over 130 different genetic variants exist 1, 2

Key genetic variants to know:

• Val122Ile (pV142I): Most common worldwide variant, present in 3-4% of African Americans (~1.5 million people in the US); predominantly causes cardiomyopathy; 10% of African Americans with heart failure over age 60 carry this variant 1, 2
• Val30Met: Most common cause of polyneuropathy; late-onset cases typically manifest with cardiac involvement 1
• Thr60Ala: Mixed phenotype with cardiomyopathy, polyneuropathy, and GI dysfunction; present in ~1% of northwest Ireland population 1

Clinical Manifestations

Cardiac Involvement (ATTR-CM)

Red flag cardiac symptoms:

• Heart failure symptoms: dyspnea, exercise intolerance, fatigue, orthopnea
• Atrial fibrillation (often treatment-resistant)
• Heart conduction block
• Restrictive cardiomyopathy physiology 1, 2

Neurologic Involvement

Polyneuropathy features:

• Progressive sensorimotor neuropathy
• Small-fiber neuropathy (not detected by conventional nerve conduction studies)
• FAP staging system for disease monitoring:
  • Stage 1: Walks unassisted
  • Stage 2: Walks with assistance (cane/walker)
  • Stage 3: Wheelchair- or bed-bound 4

Autonomic dysfunction:

• Orthostatic hypotension
• Diarrhea/constipation
• Urinary retention
• Erectile dysfunction
• Sweating abnormalities 4, 1

Other neurologic manifestations:

• Carpal tunnel syndrome (often precedes polyneuropathy by many years)
• Lumbar stenosis/lumbosacral radiculopathy (neurogenic claudication—worse with walking/standing, relieved by sitting/lying, opposite of polyneuropathy symptoms) 4

Other Systemic Manifestations

• Gastrointestinal dysfunction
• Ophthalmological involvement
• Urogenital dysfunction 3, 5

Diagnostic Approach

The diagnostic algorithm recommended by expert consensus 1:

1. Exclude light chain amyloidosis first:

   • Serum free light chain assay
   • Serum and urine immunofixation electrophoresis

2. For suspected cardiac amyloidosis with negative monoclonal protein testing:

   • Cardiac nuclear scintigraphy (technetium-labeled bone tracers)
   • Positive uptake pattern consistent with amyloidosis allows non-invasive diagnosis of ATTR-CM without biopsy 1, 2

3. If scintigraphy is equivocal or unavailable:

   • Endomyocardial or tissue biopsy with Congo red staining and immunohistochemistry

4. Once ATTR is confirmed:

   • TTR genotyping is mandatory to distinguish ATTRv from ATTRwt and identify specific mutation 1

Advanced imaging modalities:

• Echocardiographic strain imaging
• Cardiac MRI
• These aid in earlier detection and disease characterization 6

Common diagnostic pitfalls:

• Diagnosis often delayed due to heterogeneous presentation mimicking more common diseases
• Fragmented knowledge among specialists
• Perceived rarity leading to low clinical suspicion
• Misdiagnosis as hypertrophic cardiomyopathy or idiopathic neuropathy 1

Treatment Strategies

Disease-Modifying Therapies

For ATTR Cardiomyopathy (ATTR-CM):

Tafamidis (TTR stabilizer) is the only FDA-approved therapy for ATTR-CM:

• Reduces mortality from 42.9% to 29.5%
• Reduces hospitalizations from 0.7/year to 0.48/year
• Most effective when started early in disease course 2
• Note: Not FDA-approved for polyneuropathy (though approved in Europe) 4

Emerging therapies under investigation:

• Acoramidis (second-generation TTR stabilizer)
• Monoclonal antibodies targeting amyloid deposits
• Gene editing approaches 3

For ATTR Polyneuropathy (ATTRv):

Three FDA-approved TTR silencers (block RNA translation to reduce TTR production):

1. Patisiran (small interfering RNA)

   • Requires premedication with corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes before infusion to prevent infusion reactions 4

2. Vutrisiran (small interfering RNA)

   • Newer generation with improved dosing 4, 3

3. Inotersen (antisense oligonucleotide)

   • Critical monitoring required:
     • Weekly platelet counts (risk of thrombocytopenia)
     • Serum creatinine and urine protein-creatinine ratio every 2 weeks (risk of glomerulonephritis)
   • Can cause injection-site reactions 4

All TTR silencers require vitamin A supplementation (3,000 IU daily) because TTR normally transports retinol 4.

Key treatment principle: Early diagnosis and treatment is critical because patients treated earlier have significantly better outcomes in neuropathy impairment and quality of life than those whose treatment is delayed by 1 year or more 4.

Diflunisal (TTR stabilizer):

• Demonstrated effective in slowing ATTRv polyneuropathy progression
• Not FDA-approved for this indication 4

Symptomatic Management

For polyneuropathy symptoms:

• Pregabalin
• Gabapentin
• Duloxetine
• Tricyclic antidepressants 4

For orthostatic hypotension:

• Increased salt/fluid intake, salt tablets
• Fludrocortisone
• Midodrine
• Droxidopa
• Pyridostigmine

Critical caveat: All medications except pyridostigmine may be poorly tolerated in patients with cardiac involvement due to restrictive physiology 4.

For heart failure:

• Loop diuretics (furosemide, torsemide, bumetanide) are primary treatment for fluid overload and symptomatic relief 2

Prognosis and Disease Burden

• Estimated 50,000-150,000 people in the US have heart failure due to ATTR amyloidosis 2
• Global prevalence of ATTRv with cardiac involvement: approximately 40,000 of 50,000 persons with ATTRv 1
• Without treatment, median survival after ATTR-CM diagnosis is approximately 5 years 2
• Disease-modifying therapies have significantly improved survival and slowed progression 3, 5
• High symptomatic burden persists even with disease-modifying therapy, requiring comprehensive symptomatic management 5

Key Clinical Takeaways

Maintain high index of suspicion in:

• Older men with heart failure (especially African Americans over 60)
• Patients with unexplained sensorimotor neuropathy plus cardiac symptoms
• Carpal tunnel syndrome preceding heart failure by years
• Treatment-resistant atrial fibrillation with restrictive cardiomyopathy 1

The paradigm has shifted: ATTR is no longer a rare, untreatable disease but an increasingly recognized, treatable condition where early diagnosis dramatically impacts outcomes 3, 6.